Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-20-060162
Filing Date
2020-05-12
Accepted
2020-05-12 16:03:51
Documents
6
Effectiveness Date
2020-05-12

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2019153d2_defa14a.htm DEFA14A 23089
2 GRAPHIC tm2019153d2_defa14a-img01.jpg GRAPHIC 214484
3 GRAPHIC tm2019153d2_defa14a-img02.jpg GRAPHIC 297178
4 GRAPHIC tm2019153d2_defa14a-img03.jpg GRAPHIC 88380
5 GRAPHIC tm2019153d2_defa14a-img04.jpg GRAPHIC 43079
6 GRAPHIC tm2019153d2_defa14a-img05.jpg GRAPHIC 14396
  Complete submission text file 0001104659-20-060162.txt   930586
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 20869047
SIC: 2834 Pharmaceutical Preparations